Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of Global Health Burden

Journal of Pharmaceutical Sciences

Volumn 105, Issue 10, 2016, Pages 3007-3012

  Bai, Jane P F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

big data; global health; pharmacodynamics; systems pharmacology

Indexed keywords

DRUG;

ACCELERATION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG REPOSITIONING; ELECTRONIC HEALTH RECORD; HEALTH; HUMAN; KNOWLEDGE; MEDICAL INFORMATICS; NOTE; PHARMACODYNAMICS; POLYPHARMACY; PROTEIN INTERACTION; SYSTEM ANALYSIS; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG APPROVAL; ECONOMICS; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; PROCEDURES; TRENDS; ZIKA VIRUS INFECTION;

CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG REPOSITIONING; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS; PHARMACEUTICAL PREPARATIONS; ZIKA VIRUS INFECTION;

EID: 84988038440     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.07.004     Document Type: Note

References (33)

1. 1 Toriumi, D.M., Konior, R.J., Berktold, R.E., Severe hypertrichosis of the external ear canal during minoxidil therapy. Arch Otolaryngol Head Neck Surg 114 (1988), 918–919.
2. 2 Boolell, M., Gepi-Attee, S., Gingell, J.C., Allen, M.J., Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78 (1996), 257–261.
3. 3 Global Health Topics: Communicable Diseases, 2015 Available at: http://www.globalhealth.gov/global-health-topics/communicable-diseases/index.html/ Accessed December 21, 2015.
4. 4 World Health Organization. Health in 2015: From MDGs to SDGs. 2016 Available at: http://www.who.int/gho/publications/mdgs-sdgs/en/ Accessed January 1, 2016.
5. 5 Food and Drug Administration. Drugs@FDA. 2016 Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm/ Accessed January 1, 2016.
6. 6 Food and Drug Administration. Search Orphan Drug Designations and Approvals. 2016 Available at: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm Accessed June 5, 2016.
7. 7 Sands, P., Mundaca-Shah, C., Dzau, V.J., The neglected dimension of global security—a framework for countering infectious-disease crises. N Engl J Med 374 (2016), 1281–1287.
8. 8 Centers for Disease Control and Prevention. 2016. Update: Influenza Activity—Worldwide. 1996 Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00043786.htm/ Accessed January 1, 2016.
9. 9 Currie, C.J., Poole, C.D., Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. DiabetologiaI 52 (2009), 1766–1777.
10. 10 Baur, D.M., Klotsche, J., Hamnvik, O.P., et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60 (2011), 1363–1371.
11. 11 Vissers, P.A., Cardwell, C.R., van de Poll-Franse, L.V., Young, I.S., Pouwer, F., Murray, L.J., The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res Treat 150 (2015), 427–437.
12. 12 Currie, C.J., Poole, C.D., Jenkins-Jones, S., Gale, E.A., Johnson, J.A., Morgan, C.L., Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35 (2012), 299–304.
13. 13 Xu, H., Aldrich, M.C., Chen, Q., et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 22 (2015), 179–191.
14. 14 Bridges, H.R., Jones, A.J., Pollak, M.N., Hirst, J., Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462 (2014), 475–487.
15. 15 Borkar, D.S., Tham, V.M., Shen, E., et al. Association between statin use and uveitis: results from the Pacific Ocular Inflammation study. Am J Ophthalmol 159 (2015), 707–713.
16. 16 Pruefer, D., Makowski, J., Schnell, M., et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106 (2012), 2104–2110.
17. 17 Crockett, S.D., Hansen, R.A., Sturmer, T., et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 18 (2012), 1048–1056.
18. 18 Gignoux, E., Azman, A.S., de Smet, M., et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med 374 (2016), 23–32.
19. 19 Paik, H., Chung, A.Y., Park, H.C., et al. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. Sci Rep, 5, 2015, 8580.
20. 20 Sirota, M., Dudley, J.T., Kim, J., et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med, 3, 2011, 96ra77.
21. 21 Dudley, J.T., Sirota, M., Shenoy, M., et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med, 3, 2011, 96ra76.
22. 22 Crockett, S.D., Schectman, R., Sturmer, T., Kappelman, M.D., Topiramate use does not reduce flares of inflammatory bowel disease. Dig Dis Sci 59 (2014), 1535–1543.
23. 23 Hur, J., Guo, A.Y., Loh, W.Y., Feldman, E.L., Bai, J.P., Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. CPT Pharmacometrics Syst Pharmacol, 3, 2014, e114.
24. 24 Melas, I.N., Sakellaropoulos, T., Iorio, F., et al. Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury. Integr Biol (Camb) 7 (2015), 904–920.
25. 25 Jiang, P., Mukthavaram, R., Chao, Y., et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med, 12, 2014, 13.
26. 26 Bai, J.P., Burckart, G.J., Mulberg, A.E., Literature review of gastrointestinal physiology in the elderly, in pediatric patients, and in patients with gastrointestinal diseases. J Pharm Sci 105 (2016), 476–483.
27. 27 Andersson, J.A., Fitts, E.C., Kirtley, M.L., et al. New role for FDA-approved drugs in combating antibiotic-resistant bacteria. Antimicrobial Agents Chemother 60 (2016), 3717–3729.
28. 28 Kim, C.H., Han, B.S., Moon, J., et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. Proc Natl Acad Sci U S A 112 (2015), 8756–8761.
29. 29 Rybniker, J., Vocat, A., Sala, C., et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat Commun, 6, 2015, 7659.
30. 30 Bekerman, E., Einav, S., Infectious disease. Combating emerging viral threats. Science 348 (2015), 282–283.
31. 31 Hamel, R., Dejarnac, O., Wichit, S., et al. Biology of Zika virus infection in human skin cells. J Virol 89 (2015), 8880–8896.
32. 32 Perera-Lecoin, M., Meertens, L., Carnec, X., Amara, A., Flavivirus entry receptors: an update. Viruses 6 (2014), 69–88.
33. 33 Prieto, A.L., Weber, J.L., Lai, C., Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system. J Comp Neurol 425 (2000), 295–314.